-
公开(公告)号:US20240269160A1
公开(公告)日:2024-08-15
申请号:US18418193
申请日:2024-01-19
发明人: Chen CHEN , Huaping LI , Daowen WANG , Beibei DAI
IPC分类号: A61K31/7068 , A01K67/027 , A61P43/00 , C12N15/113 , C12N15/86
CPC分类号: A61K31/7068 , A01K67/027 , A61P43/00 , C12N15/113 , C12N15/86 , A01K2207/05 , A01K2267/0306 , C12N2310/122 , C12N2750/14143
摘要: The present invention of use of citicoline in regulating respiratory chain function related protein level and preparing drug for preventing and treating respiratory chain dysfunction belongs to the field of drug. The present invention provides use of citicoline in regulating respiratory chain function related protein level, and also provides use of citicoline in preparing drug for preventing and treating respiratory chain dysfunction. The present invention also provides a shRNA causing respiratory chain dysfunction, its reverse complementary sequence is shown as SEQ ID NO. 2. The present invention also provides use of shRNA in preparing a respiratory chain dysfunction animal model, as well as its preparation method. It's confirmed by experiments that citicoline can effectively reverse molecular level symptoms of respiratory chain dysfunction and can be used as a drug for treating respiratory chain dysfunction.
-
公开(公告)号:US20240138383A1
公开(公告)日:2024-05-02
申请号:US18316688
申请日:2023-05-12
申请人: GloFish LLC
IPC分类号: A01K67/0275 , A01K67/027 , C07K14/435 , C12N15/85 , G06Q99/00
CPC分类号: A01K67/0275 , A01K67/027 , C07K14/43595 , C12N15/8509 , G06Q99/00 , A01K2217/05 , A01K2217/052 , A01K2217/206 , A01K2227/40 , A01K2267/0393 , C12N2830/008
摘要: The present invention relates to the method and use of reef coral fluorescent proteins in making transgenic red, green and yellow fluorescent zebrafish. Preferably, such fluorescent zebrafish are fertile and used to establish a population of transgenic zebrafish and to provide to the ornamental fish industry for the purpose of marketing. Thus, new varieties of ornamental fish of different fluorescence colors from a novel source are developed.
-
公开(公告)号:US11963520B2
公开(公告)日:2024-04-23
申请号:US16070769
申请日:2017-01-18
申请人: Celgene Corporation
发明人: Rajesh Chopra , Anke Klippel
IPC分类号: A01K67/027 , A01K67/0278 , A61K39/00 , G01N33/574
CPC分类号: A01K67/0278 , A61K39/001102 , G01N33/57484 , A01K2217/072 , A01K2227/105 , A01K2267/03 , A01K2267/0331
摘要: Provided are transgenic mice whose genome comprises a nucleic acid sequence encoding human cereblon (CRBN) or a fragment thereof, wherein endogenous mouse CRBN is not expressed in the transgenic mice. Also provided are cells, cell lines, tissues, and organs derivable from the transgenic mice, and methods for producing and using such mice.
-
公开(公告)号:US20240114883A1
公开(公告)日:2024-04-11
申请号:US18233507
申请日:2023-08-14
发明人: Wei Weng
IPC分类号: A01K67/027 , C07K14/725
CPC分类号: A01K67/0278 , A01K67/0276 , C07K14/7051 , A01K2207/12 , A01K2207/15 , A01K2217/052 , A01K2217/072 , A01K2217/075 , A01K2217/15 , A01K2227/105 , A01K2267/01 , A01K2267/0331
摘要: The invention provides a genetically modified non-human animal that comprises in its genome foreign γ and δ T cell receptor variable gene coding fragments, as well as its tissues, embryos, and cells. Also provided are constructs and methods for making said genetically modified non-human animal. Human T cell receptor (TCR) cloning and repertoire analysis are also included. Applications for using said animal in infectious diseases are also provided.
-
公开(公告)号:US11938191B2
公开(公告)日:2024-03-26
申请号:US16864613
申请日:2020-05-01
发明人: Sean D. Monahan , Michael S. Declue , Pierrot Harvie , Russell N. Johnson , Amber E. Paschal , Mary G. Prieve , Debashish Roy , Charbel Diab , Michael E. Houston, Jr. , Anna Galperin , Maher Qabar
IPC分类号: A61K47/64 , A01K67/027 , A61K38/08 , A61K38/44 , A61K47/54 , A61K47/58 , A61K48/00 , C08F293/00 , C12N15/113 , C12N15/87
CPC分类号: A61K47/6455 , A01K67/027 , A61K38/08 , A61K38/44 , A61K47/549 , A61K47/58 , A61K48/0041 , C08F293/005 , C12N15/113 , C12N15/87 , A01K2207/05 , C12N2310/14 , C12N2310/351 , C12N2320/32 , C12Y113/12007
摘要: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.
-
公开(公告)号:US20240090481A1
公开(公告)日:2024-03-21
申请号:US18467037
申请日:2023-09-14
申请人: Joseph Fenton LAWLER
发明人: Joseph Fenton LAWLER
IPC分类号: A01K67/027
CPC分类号: A01K67/0275 , A01K2217/30 , A01K2227/30
摘要: Described herein are methods and compositions for generating single sex offspring using trans-splicing approach. In particular, methods and compositions are provided to generate single sex and genetically modified offspring. These techniques can be applied to compassionate animal breeding.
-
公开(公告)号:US20240090479A1
公开(公告)日:2024-03-21
申请号:US18262541
申请日:2022-01-27
申请人: ABS Global, Inc.
IPC分类号: A01K67/027 , C12N9/22
CPC分类号: A01K67/0275 , C12N9/22 , A01K2227/101 , C12N2310/10
摘要: Provided are genetically edited animals, particularly dairy animals such as cows or heifers, that lactate without having first been pregnant. Also provided are methods and reagents for creating genetically modified animals. Specifically provided are genetically edited dairy animals that have a histidine to arginine substitution in the prolactin receptor gene.
-
8.
公开(公告)号:US20240081302A1
公开(公告)日:2024-03-14
申请号:US18486336
申请日:2023-10-13
IPC分类号: A01K67/027 , C07K16/06 , C12N9/22 , C12N15/85 , C12N15/90
CPC分类号: A01K67/0278 , C07K16/06 , C12N9/22 , C12N15/8509 , C12N15/907 , A01K2217/072 , A01K2217/15 , A01K2227/105 , A01K2267/01
摘要: A method of preparing an antibody carrying a universal site-directed coupling interface based on a genetically modified vertebrate is described. The method of constructs a vertebrate model, the vertebrate model is used to produce an antibody carrying a universal site-directed coupling interface. The method includes site-directly knocking in a coding gene of a specific recognition sequence of a certain ligase A or a coding gene of a certain intein A at a certain position A of a certain coding gene A of the immunoglobulin in the genome of the recipient animal, to obtain the vertebrate model. The modified mice can normally stimulate immune responses, produce a polyclonal antibody and a monoclonal antibody with a site-directed linking site. Antibodies with a site-directed linking site can normally carry out site-directed linking, and add various application groups to realize downstream applications of antibodies, such as ELISA, immunofluorescence staining, and immuno-PCR.
-
公开(公告)号:US20240074416A1
公开(公告)日:2024-03-07
申请号:US18368130
申请日:2023-09-14
发明人: Mark Albert Scheideler , Guojun Zhao , John Svaren , David C. Chan , Steven S. Scherer , Taleen Hanania
IPC分类号: A01K67/027 , C12N9/14
CPC分类号: A01K67/0278 , C12N9/14 , A01K2217/075 , A01K2227/105 , A01K2267/0356 , C12Y306/05
摘要: The present invention relates to the engineering an animal model, preferably mammalian models, more preferably a rat model representing Charcot-Marie-Tooth disease 2A (CMT2A) harboring the p.Arg364Trp or p.His361Tyr Mfn2 mutation, whose human counterpart results in a severe, early-onset axonal neuropathy. A model having the p.Arg364Trp Mfn2 mutation is based on a mutation made using zinc finger endonuclease technology in fertilized rat eggs. Cohorts of mutants and wild type littermates were characterized behaviorally and shown to develop multiple motor deficits that worsened over time. Separate cohorts of mutant and wild type rats sacrificed at 7, 40, and 48 weeks and analyzed by light microscopy showed a reduced density of myelinated axons and active axonal degeneration in distal but not proximal nerves, as well as axonal degeneration in the fasciculus gracilis of the cervical spinal cord at 40 and 48 weeks. These findings were not present in the 7-week-old cohort of Mfn2 mutants, or in wild type rats at 7 or 40 weeks. A model having the p.His361Tyr Mfn2 mutation is based on a mutation made using CRISPR/Cas9 gene editing technology. This mutation showed abnormalities in gait dynamics at 8 weeks and a lengthening of the gait cycle at 16 weeks. A genetically authentic animal model for CMT2A developing a progressive axonal neuropathy is a valuable tool for examining the pathogenesis and treatment of CMT2A.
-
公开(公告)号:US20240065238A1
公开(公告)日:2024-02-29
申请号:US18137110
申请日:2023-04-20
IPC分类号: A01K67/027 , C07K16/46 , C12P21/02
CPC分类号: A01K67/0278 , A01K67/0276 , C07K16/461 , C12P21/02 , A01K2207/15 , A01K2217/072 , A01K2217/075 , A01K2217/15 , A01K2227/105
摘要: Mice, embryos, cells, and tissues having a restricted immunoglobulin heavy chain locus and an ectopic sequence encoding one or more ADAM6 proteins are provided. In various embodiments, mice are described that have humanized endogenous immunoglobulin heavy chain loci and are capable of expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof that is functional in a male mouse. Mice, embryos, cells, and tissues having an immunoglobulin heavy chain locus characterized by a single human VH gene segment, a plurality of human DH gene segments and a plurality of human JH gene segments and capable expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof are also provided.
-
-
-
-
-
-
-
-
-